1. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer cell 2015;27(4):450-61. doi: 10.1016/j.ccell.2015.03.001 [published Online First: 2015/04/11]
2. Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. The New England journal of medicine 2018;378(2):158-68. doi: 10.1056/NEJMra1703481 [published Online First: 2018/01/11]
3. Cappelli LC, Gutierrez AK, Bingham CO, 3rd, et al. Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. Arthritis care & research 2017;69(11):1751-63. doi: 10.1002/acr.23177 [published Online First: 2016/12/21]
4. Abdel-Wahab N, Suarez-Almazor ME. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy. Rheumatology (Oxford, England) 2019;58(Suppl 7):vii40-vii48. doi: 10.1093/rheumatology/kez297 [published Online First: 2019/12/10]
5. Calabrese LH, Calabrese C, Cappelli LC. Rheumatic immune-related adverse events from cancer immunotherapy. Nature reviews Rheumatology 2018 doi: 10.1038/s41584-018-0074-9 [published Online First: 2018/09/02]
6. Narvaez J, Juarez-Lopez P, J LL, et al. Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy. Autoimmunity reviews 2018;17(10):1040-45. doi: 10.1016/j.autrev.2018.05.002 [published Online First: 2018/08/14]
7. Warner BM, Baer AN, Lipson EJ, et al. Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. The oncologist 2019;24(9):1259-69. doi: 10.1634/theoncologist.2018-0823 [published Online First: 2019/04/19]
8. Touat M, Maisonobe T, Knauss S, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology 2018;91(10):e985-e94. doi: 10.1212/wnl.0000000000006124 [published Online First: 2018/08/10]
9. Seki M, Uruha A, Ohnuki Y, et al. Inflammatory myopathy associated with PD-1 inhibitors. Journal of autoimmunity 2019;100:105-13. doi: 10.1016/j.jaut.2019.03.005 [published Online First: 2019/03/14]
10. Shelly S, Triplett JD, Pinto MV, et al. Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy. Brain communications 2020;2(2):fcaa181. doi: 10.1093/braincomms/fcaa181 [published Online First: 2020/12/12]
11. Braaten TJ, Brahmer JR, Forde PM, et al. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Annals of the rheumatic diseases 2020;79(3):332-38. doi: 10.1136/annrheumdis-2019-216109 [published Online First: 2019/09/22]
12. Cappelli LC, Brahmer JR, Forde PM, et al. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Seminars in arthritis and rheumatism 2018;48(3):553-57. doi: 10.1016/j.semarthrit.2018.02.011 [published Online First: 2018/03/27]
13. Ghosh N, Tiongson MD, Stewart C, et al. Checkpoint Inhibitor-Associated Arthritis: A Systematic Review of Case Reports and Case Series. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2020 doi: 10.1097/rhu.0000000000001370 [published Online First: 2020/04/30]
14. Albayda J, Dein E, Shah AA, et al. Sonographic Findings in Inflammatory Arthritis Secondary to Immune Checkpoint Inhibition: A Case Series. ACR open rheumatology 2019;1(5):303-07. doi: 10.1002/acr2.1026 [published Online First: 2019/11/30]
15. Bronstein Y, Ng CS, Hwu P, et al. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol 2011;197(6):W992-w1000. doi: 10.2214/ajr.10.6198 [published Online First: 2011/11/24]
16. Cencini E, Bocchia M, Fabbri A. Nivolumab in relapsed/refractory Hodgkin lymphoma: towards a new treatment strategy? American journal of blood research 2021;11(3):261-65. [published Online First: 2021/07/30]
17. Kim ST, Tayar J, Trinh VA, et al. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Annals of the rheumatic diseases 2017;76(12):2061-64. doi: 10.1136/annrheumdis-2017-211560 [published Online First: 2017/08/24]
18. Roberts J, Smylie M, Walker J, et al. Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis. Clinical rheumatology 2019;38(5):1513-19. doi: 10.1007/s10067-019-04451-2 [published Online First: 2019/02/01]
19. Yang X, Wang M, Zhang X, et al. Diagnostic accuracy of anti-RA33 antibody for rheumatoid arthritis: systematic review and meta-analysis. Clinical and experimental rheumatology 2016;34(3):539-47. [published Online First: 2016/04/07]
20. Konig MF, Giles JT, Nigrovic PA, et al. Antibodies to native and citrullinated RA33 (hnRNP A2/B1) challenge citrullination as the inciting principle underlying loss of tolerance in rheumatoid arthritis. Annals of the rheumatic diseases 2016;75(11):2022-28. doi: 10.1136/annrheumdis-2015-208529 [published Online First: 2016/02/13]
21. Belkhir R, Burel SL, Dunogeant L, et al. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Annals of the rheumatic diseases 2017;76(10):1747-50. doi: 10.1136/annrheumdis-2017-211216 [published Online First: 2017/06/11]
22. Joseph CG, Darrah E, Shah AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science (New York, NY) 2014;343(6167):152-7. doi: 10.1126/science.1246886 [published Online First: 2013/12/07]
23. Pinal-Fernandez I, Ferrer-Fabregas B, Trallero-Araguas E, et al. Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis. Rheumatology (Oxford, England) 2018;57(2):388-96. doi: 10.1093/rheumatology/kex413 [published Online First: 2017/11/18]
24. Golan-Gerstl R, Cohen M, Shilo A, et al. Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. Cancer research 2011;71(13):4464-72. doi: 10.1158/0008-5472.can-10-4410 [published Online First: 2011/05/19]
25. Shilo A, Ben Hur V, Denichenko P, et al. Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development. RNA (New York, NY) 2014;20(4):505-15. doi: 10.1261/rna.042259.113 [published Online First: 2014/02/28]
26. Zhou J, Nong L, Wloch M, et al. Expression of early lung cancer detection marker: hnRNP-A2/B1 and its relation to microsatellite alteration in non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2001;34(3):341-50. [published Online First: 2001/11/21]